{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:03:48Z","timestamp":1778814228243,"version":"3.51.4"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms that are characterized by thrombohemorrhagic complications, symptom burden, and impaired survival mainly due to thrombosis, progression to myelofibrosis, and transformation to acute leukemia. In this manuscript, we will review the most recent changes in diagnostic criteria, the improvements in risk stratification, and the \u201cstate of the art\u201d in the daily management of these disorders. The role of conventional therapies and novel agents, interferon \u03b1 and the JAK2 inhibitor ruxolitinib, is critically discussed based on the results of a few basic randomized clinical studies. Several unmet needs remain, above all, the lack of a curative approach that might overcome the still burdensome morbidity and mortality of these hematologic neoplasms, as well as the toxicities associated with therapeutic agents.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.480","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"480-488","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?"],"prefix":"10.1182","volume":"2017","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Careggi University Hospital\/University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Careggi University Hospital\/University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"16","key":"2019111704245150000_B1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111704245150000_B2","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111704245150000_B3","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111704245150000_B4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111704245150000_B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111704245150000_B6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111704245150000_B7","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.6004\/jnccn.2016.0133","article-title":"Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era","volume":"14","author":"Kander","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2019111704245150000_B8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00432-016-2209-1","article-title":"Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany","volume":"142","author":"Jentsch-Ullrich","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2019111704245150000_B9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111704245150000_B10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.6004\/jnccn.2016.0169","article-title":"Myeloproliferative neoplasms, version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Mesa","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"2019111704245150000_B11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2019111704245150000_B12","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111704245150000_B13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1080\/10428194.2017.1300892","article-title":"Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera","volume":"58","author":"Silver","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111704245150000_B14","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111704245150000_B15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111704245150000_B16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"issue":"23","key":"2019111704245150000_B17","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111704245150000_B18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111704245150000_B19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111704245150000_B20","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"2019111704245150000_B21","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"2019111704245150000_B22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111704245150000_B23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"Chu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111704245150000_B24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111704245150000_B25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2019111704245150000_B26","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"2019111704245150000_B27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111704245150000_B28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"17","key":"2019111704245150000_B29","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111704245150000_B30","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704245150000_B31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2019111704245150000_B32","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111704245150000_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.475.475","article-title":"Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients [abstract]","volume":"128","author":"Gisslinger","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111704245150000_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.479.479","article-title":"Interim analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia [abstract]","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111704245150000_B35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111704245150000_B36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111704245150000_B37","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials","volume":"102","author":"Barbui","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2019111704245150000_B38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111704245150000_B39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111704245150000_B40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111704245150000_B41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111704245150000_B42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111704245150000_B43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111704245150000_B44","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2019111704245150000_B45","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"2019111704245150000_B46","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results [published online ahead of print August 21, 2017]","author":"Verstovsek","journal-title":"Blood"},{"issue":"8","key":"2019111704245150000_B47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2019111704245150000_B48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111704245150000_B49","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"Patrono","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111704245150000_B50","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"key":"2019111704245150000_B51","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms [published online ahead of print 16 June 2017]","author":"Ianotto","journal-title":"Int J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/480\/1250090\/hem00067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/480\/1250090\/hem00067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:25:13Z","timestamp":1573982713000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/480\/21108\/What-are-the-current-treatment-approaches-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.480","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}